S1105 |
LY294002
|
LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis. |
-
Signal Transduct Target Ther, 2024, 9(1):109
-
Signal Transduct Target Ther, 2024, 9(1):109
-
Nat Genet, 2024, 10.1038/s41588-024-01891-8
|
|
S2248 |
Silmitasertib (CX-4945)
|
Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Silmitasertib induces autophagy and promotes apoptosis. Phase 1/2. |
-
Metabolism, 2025, 162:156060
-
Diabetologia, 2024, 10.1007/s00125-024-06128-1
-
Biomed Pharmacother, 2024, 180:117499
|
|
S7085 |
IWP-2
|
IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ. |
-
Cell Stem Cell, 2024, S1934-5909(24)00256-X
-
Nat Commun, 2024, 15(1):1351
-
Nat Commun, 2024, 15(1):167
|
|
S0707 |
Silmitasertib (CX-4945) sodium salt
|
Silmitasertib (CX-4945) sodium salt is a potent, orally bioavailable and selective inhibitor of casein kinase 2 (CK2) with IC50 of 1 nM against CK2α and CK2α'. |
-
Diabetologia, 2024, 10.1007/s00125-024-06128-1
-
J Diabetes Investig, 2024, 15(6):684-692
-
Proc Natl Acad Sci U S A, 2022, 119(12):e2114336119
|
|
S2805 |
LY364947
|
LY364947 (HTS 466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM in a cell-free assay, shows 7-fold selectivity over TGFβR-II. |
-
Adv Sci (Weinh), 2024, 11(4):e2304987
-
Cell Rep Med, 2024, 5(2):101416
-
Cell Commun Signal, 2024, 22(1):242
|
|
S7642 |
D 4476
|
D 4476 is a potent, selective, and cell-permeant CK1 (casein kinase 1) inhibitor with IC50 of 200 nM and 300 nM in a cell-free assay for CK1 from Schizosaccharomyces pombe and CK1δ, respectively. Also acts as an ALK5 inhibitor with IC50 of 500 nM.
|
-
Cell Rep Med, 2023, 4(4):101015
-
Cell Rep, 2023, 42(9):113035
-
Nat Commun, 2022, 13(1):3034
|
|
S5265 |
TBB
|
TBB (4,5,6,7-tetrabromobenzotriazole) is a selective cell-permeable CK2 inhibitor with IC50 values of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively. |
-
Cell Rep, 2024, 43(2):113779
-
Mol Cell, 2023, 83(15):2792-2809.e9
-
Cancers (Basel), 2022, 15(1)200
|
|
S8237 |
IC261
|
IC261 (SU-5607) is a novel inhibitor of CK1. The IC50 of IC261 for CK1 is 16 μM and for Cdk5 is 4.5 mM. |
-
Cell Rep, 2023, 42(7):112812
-
Cell Metab, 2022, S1550-4131(21)00542-8
-
Sci Rep, 2022, 12(1):7
|
|
S9850 |
(E/Z)-GO289
|
(E/Z)-GO289 potently and selectively inhibits casein kinase 2 (CK2) at an IC50 of 7 nM in vitro kinase assay.
|
-
Autophagy, 2023, 10.1080/15548627.2023.2281128
|
|
S6536 |
TTP 22
|
TTP22 is a casein kinase 2 (CK2) inhibitor with an IC50 value of 100 nM. It displays selectivity for CK2 over JNK3, ROCK1, and MET with no inhibitory effects towards these kinases at 10 μM. |
-
J Cell Biol, 2022, 221-11e202202100
|
|
S6578 |
Longdaysin
|
Longdaysin is a Casein Kinase inhibitor with IC50 values of 8.8 μM, 5.6 μM, 52 μM and 29 μM for CKIδ, CKIα, ERK2 and CDK7. |
-
Nat Commun, 2021, 12(1):7003
|
|
S2249 |
PF 4800567
|
PF 4800567 is a novel and potent inhibitor of casein kinase 1 epsilon (IC50=32 nM) with greater than 20-fold selectivity over casein kinase 1 delta(IC50=711 nM). |
-
Blood Adv, 2020, 4(13):3072-3084
|
|
S5516 |
Ellagic Acid hydrate
|
Ellagic acid is a potent inhibitor of protein kinase CK2 with IC50s of 0.04, 2.9 and 3.5 μM for CK2, Lyn and PKA respectively. It shows potent antioxidant, anti-mutagenic and antidepressant properties. |
-
J Cell Biol, 2022, 221-11e202202100
|
|
S9331 |
7-Hydroxy-4-methyl-8-nitrocoumarin
|
7-Hydroxy-4-methyl-8-nitrocoumarin is a chemical. |
|
|
S6544 |
SR-3029
|
SR-3029 is a potent and selective casein kinase 1δ/1ε (CK1δ/ε) inhibitor with IC50 values of 44 and 260 nM for CK1δ and CK1ε, respectively. |
|
|
E1413 |
DEG-77
|
DEG-77 is a cereblon-dependent degrader of IKZF2 and casein kinase 1α (CK1α). It blocks cell growth and delays leukemia progression in murine and human acute myeloid leukemia (AML) mouse models. |
|
|
E1412 |
DEG-35
|
DEG-35 is a cereblon-dependent degrader of IKZF2 and casein kinase 1α (CK1α). It blocks cell growth and delays leukemia progression in murine and human acute myeloid leukemia (AML) mouse models. |
|
|
S3143 |
Pyruvic acid
|
Pyruvic acid (Acetylformic acid) is an important organic chemical intermediate that plays a role in cardiomyocyte pathophysiology and therapy. Pyruvic acid markedly increases the level of lactate dehydrogenase (LDH) and creatine kinase (CK) and reduces the level of Ca2+Mg2+-ATPase and Na+K+-ATPase. |
|
|
E1927New |
PF-05251749(CK1-IN-2)
|
PF-05251749 (CK1-IN-2, Compound Nr.4) is a potent, selective, brain-penetrant inhibitor of Casein Kinase 1 (CK1) in a concentration-dependent manner, with IC50 values of 33.1 nM for CK1d and 51.6 nM for CK1e. It also functions as an inducer of CYP3A, with the potential to treat circadian rhythm disruptions in Alzheimer's and Parkinson's diseases. |
|
|
S0350 |
CK1-IN-1
|
CK1-IN-1 (PUN51207, Compound 1C) is an inhibitor of casein kinase 1 (CK1) with IC50 of 15 nM, 16 nM and 73 nM for CK1δ, CK1ε and p38α MAPK, respectively. |
|
|
S0995 |
BioE-1115
|
BioE-1115 is a highly selective and potent dual inhibitor of PAS kinase (PASK) and casein kinase 2α (CK2α) with IC50 of ~4 nM and ~10 μM, respectively. |
|
|
E2914 |
5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside
|
5,6-Dichlorobenzimidazole riboside(DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II and CDKs. It trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells. |
|
|
S6734 |
PF-670462
|
PF-670462 is a potent and selective inhibitor of CK1ε and CK1δ with IC50 value of 90 nM and 13 nM, respectively. |
-
J Biomed Sci, 2024, 31(1):72
|
|
E2659 |
DMAT
|
DMAT is a high affinity and selective casein kinase-2 (CK2) inhibitor with IC50 of ~0.14 μM and Ki of ~40 nM. |
|
|
E2506 |
A-3 hydrochloride
|
A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively. |
|
|
E2826 |
Hematein
|
Hematein inhibits casein kinase II activity in a selective, dose-dependent and ATP non-competitive manner in vitro, with IC50 of 0.55 μM in the presence of 10 μM ATP. |
|
|
S0186 |
TA-01
|
TA-01 is a potent inhibitor of CK1δ/ε and p38 MAPK with IC50 of 6.4 nM, 6.8 nM and 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.
|
|
|
S1105 |
LY294002
|
LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis. |
- Signal Transduct Target Ther, 2024, 9(1):109
- Signal Transduct Target Ther, 2024, 9(1):109
- Nat Genet, 2024, 10.1038/s41588-024-01891-8
|
|
S2248 |
Silmitasertib (CX-4945)
|
Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Silmitasertib induces autophagy and promotes apoptosis. Phase 1/2. |
- Metabolism, 2025, 162:156060
- Diabetologia, 2024, 10.1007/s00125-024-06128-1
- Biomed Pharmacother, 2024, 180:117499
|
|
S7085 |
IWP-2
|
IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ. |
- Cell Stem Cell, 2024, S1934-5909(24)00256-X
- Nat Commun, 2024, 15(1):1351
- Nat Commun, 2024, 15(1):167
|
|
S0707 |
Silmitasertib (CX-4945) sodium salt
|
Silmitasertib (CX-4945) sodium salt is a potent, orally bioavailable and selective inhibitor of casein kinase 2 (CK2) with IC50 of 1 nM against CK2α and CK2α'. |
- Diabetologia, 2024, 10.1007/s00125-024-06128-1
- J Diabetes Investig, 2024, 15(6):684-692
- Proc Natl Acad Sci U S A, 2022, 119(12):e2114336119
|
|
S2805 |
LY364947
|
LY364947 (HTS 466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM in a cell-free assay, shows 7-fold selectivity over TGFβR-II. |
- Adv Sci (Weinh), 2024, 11(4):e2304987
- Cell Rep Med, 2024, 5(2):101416
- Cell Commun Signal, 2024, 22(1):242
|
|
S7642 |
D 4476
|
D 4476 is a potent, selective, and cell-permeant CK1 (casein kinase 1) inhibitor with IC50 of 200 nM and 300 nM in a cell-free assay for CK1 from Schizosaccharomyces pombe and CK1δ, respectively. Also acts as an ALK5 inhibitor with IC50 of 500 nM.
|
- Cell Rep Med, 2023, 4(4):101015
- Cell Rep, 2023, 42(9):113035
- Nat Commun, 2022, 13(1):3034
|
|
S5265 |
TBB
|
TBB (4,5,6,7-tetrabromobenzotriazole) is a selective cell-permeable CK2 inhibitor with IC50 values of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively. |
- Cell Rep, 2024, 43(2):113779
- Mol Cell, 2023, 83(15):2792-2809.e9
- Cancers (Basel), 2022, 15(1)200
|
|
S8237 |
IC261
|
IC261 (SU-5607) is a novel inhibitor of CK1. The IC50 of IC261 for CK1 is 16 μM and for Cdk5 is 4.5 mM. |
- Cell Rep, 2023, 42(7):112812
- Cell Metab, 2022, S1550-4131(21)00542-8
- Sci Rep, 2022, 12(1):7
|
|
S9850 |
(E/Z)-GO289
|
(E/Z)-GO289 potently and selectively inhibits casein kinase 2 (CK2) at an IC50 of 7 nM in vitro kinase assay.
|
- Autophagy, 2023, 10.1080/15548627.2023.2281128
|
|
S6536 |
TTP 22
|
TTP22 is a casein kinase 2 (CK2) inhibitor with an IC50 value of 100 nM. It displays selectivity for CK2 over JNK3, ROCK1, and MET with no inhibitory effects towards these kinases at 10 μM. |
- J Cell Biol, 2022, 221-11e202202100
|
|
S6578 |
Longdaysin
|
Longdaysin is a Casein Kinase inhibitor with IC50 values of 8.8 μM, 5.6 μM, 52 μM and 29 μM for CKIδ, CKIα, ERK2 and CDK7. |
- Nat Commun, 2021, 12(1):7003
|
|
S2249 |
PF 4800567
|
PF 4800567 is a novel and potent inhibitor of casein kinase 1 epsilon (IC50=32 nM) with greater than 20-fold selectivity over casein kinase 1 delta(IC50=711 nM). |
- Blood Adv, 2020, 4(13):3072-3084
|
|
S5516 |
Ellagic Acid hydrate
|
Ellagic acid is a potent inhibitor of protein kinase CK2 with IC50s of 0.04, 2.9 and 3.5 μM for CK2, Lyn and PKA respectively. It shows potent antioxidant, anti-mutagenic and antidepressant properties. |
- J Cell Biol, 2022, 221-11e202202100
|
|
S9331 |
7-Hydroxy-4-methyl-8-nitrocoumarin
|
7-Hydroxy-4-methyl-8-nitrocoumarin is a chemical. |
|
|
S6544 |
SR-3029
|
SR-3029 is a potent and selective casein kinase 1δ/1ε (CK1δ/ε) inhibitor with IC50 values of 44 and 260 nM for CK1δ and CK1ε, respectively. |
|
|
E1927New |
PF-05251749(CK1-IN-2)
|
PF-05251749 (CK1-IN-2, Compound Nr.4) is a potent, selective, brain-penetrant inhibitor of Casein Kinase 1 (CK1) in a concentration-dependent manner, with IC50 values of 33.1 nM for CK1d and 51.6 nM for CK1e. It also functions as an inducer of CYP3A, with the potential to treat circadian rhythm disruptions in Alzheimer's and Parkinson's diseases. |
|
|
S0350 |
CK1-IN-1
|
CK1-IN-1 (PUN51207, Compound 1C) is an inhibitor of casein kinase 1 (CK1) with IC50 of 15 nM, 16 nM and 73 nM for CK1δ, CK1ε and p38α MAPK, respectively. |
|
|
S0995 |
BioE-1115
|
BioE-1115 is a highly selective and potent dual inhibitor of PAS kinase (PASK) and casein kinase 2α (CK2α) with IC50 of ~4 nM and ~10 μM, respectively. |
|
|
E2914 |
5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside
|
5,6-Dichlorobenzimidazole riboside(DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II and CDKs. It trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells. |
|
|
S6734 |
PF-670462
|
PF-670462 is a potent and selective inhibitor of CK1ε and CK1δ with IC50 value of 90 nM and 13 nM, respectively. |
- J Biomed Sci, 2024, 31(1):72
|
|
E2659 |
DMAT
|
DMAT is a high affinity and selective casein kinase-2 (CK2) inhibitor with IC50 of ~0.14 μM and Ki of ~40 nM. |
|
|
E2826 |
Hematein
|
Hematein inhibits casein kinase II activity in a selective, dose-dependent and ATP non-competitive manner in vitro, with IC50 of 0.55 μM in the presence of 10 μM ATP. |
|
|
S0186 |
TA-01
|
TA-01 is a potent inhibitor of CK1δ/ε and p38 MAPK with IC50 of 6.4 nM, 6.8 nM and 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.
|
|
|